Globe says group wants to oust Dimethaid board, CEO
Dimethaid Research Inc DMX
Shares issued 75,967,915 May 11 close $0.73
Wed 12 May 2004 In the News
The Globe and Mail reports in its Wednesday, May 12, edition that a
dissident group of shareholders of Dimethaid Research of Markham, Ont.,
wants to replace the drug company's board and its chief executive officer
Rebecca Keeler. The Globe's In Brief column reports that the company said
the group, which it did not identify, owns more than 5 per cent of
Dimethaid's stock and can petition for a meeting of shareholders to approve
a new slate of directors. The company did not elaborate on its discussions
with the group and Ms. Keeler could not be reached for comment. Dimethaid
stock closed unchanged at 73 cents on the Toronto Stock Exchange Tuesday.
The stock has a 52-week high price of $2.08, which it set in May, 2003, and
a 52-week low price of 69 cents which it set on Monday.
(c) Copyright 2004 Canjex Publishing Ltd. stockwatch.com |
